Evaluating the performance of copula models in phase I-II clinical trials under model misspecification

BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunanan, Kristen, Koopmeiners, Joseph S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234400/
https://www.ncbi.nlm.nih.gov/pubmed/24731155
http://dx.doi.org/10.1186/1471-2288-14-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234400/
https://www.ncbi.nlm.nih.gov/pubmed/24731155
http://dx.doi.org/10.1186/1471-2288-14-51

Ejemplares similares